Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Inventory (2017 - 2025)

Neurocrine Biosciences' Change in Inventory history spans 9 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Change in Inventory fell 70.69% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $15.3 million, down 19.9%, while the annual FY2025 figure was $15.3 million, 19.9% down from the prior year.
  • Change in Inventory reached $3.4 million in Q4 2025 per NBIX's latest filing, down from $12.3 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $12.3 million in Q3 2025 to a low of -$3.9 million in Q4 2022.
  • Average Change in Inventory over 5 years is $1.7 million, with a median of $600000.0 recorded in 2022.
  • Peak YoY movement for Change in Inventory: crashed 633.33% in 2023, then surged 1188.89% in 2024.
  • A 5-year view of Change in Inventory shows it stood at $5.0 million in 2021, then crashed by 178.0% to -$3.9 million in 2022, then surged by 123.08% to $900000.0 in 2023, then soared by 1188.89% to $11.6 million in 2024, then tumbled by 70.69% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Change in Inventory are $3.4 million (Q4 2025), $12.3 million (Q3 2025), and -$2.1 million (Q2 2025).